Docetaxel and / or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476) - James, N D; Sydes, M R; Mason, M D (J Clin Oncol, 2015)
(suppl): abstr 5001